Table 1. Demographic and Clinical Characteristics of the Patients at Baseline According to Remdesivir Treatment Group.*.
| Characteristic | 5-Day Group (N=200) |
10-Day Group (N=197) |
|---|---|---|
| Median age (IQR) — yr | 61 (50–69) | 62 (50–71) |
| Male sex — no. (%) | 120 (60) | 133 (68) |
| Race — no./total no. (%)† | ||
| White | 142/200 (71) | 134/192 (70) |
| Black | 21/200 (10) | 23/192 (12) |
| Asian | 20/200 (10) | 25/192 (13) |
| Other | 17/200 (8) | 10/192 (5) |
| Median body-mass index (IQR)‡ | 29 (25–34) | 29 (25–33) |
| Coexisting conditions of interest — no. (%) | ||
| Diabetes | 47 (24) | 43 (22) |
| Hyperlipidemia | 40 (20) | 49 (25) |
| Hypertension | 100 (50) | 98 (50) |
| Asthma | 27 (14) | 22 (11) |
| Clinical status on the 7-point ordinal scale — no. (%)§ | ||
| 2: Receiving invasive mechanical ventilation or ECMO | 4 (2) | 9 (5) |
| 3: Receiving noninvasive ventilation or high-flow oxygen | 49 (24) | 60 (30) |
| 4: Receiving low-flow supplemental oxygen | 113 (56) | 107 (54) |
| 5: Not receiving supplemental oxygen but requiring medical care | 34 (17) | 21 (11) |
| Median duration of hospitalization before first dose of remdesivir (IQR) — days | 2 (1–3) | 2 (1–3) |
| Median duration of symptoms before first dose of remdesivir (IQR) — days | 8 (5–11) | 9 (6–12) |
| Median AST level (IQR) — U/liter¶ | 41 (29–58) | 46 (34–67) |
| Median ALT level (IQR) — U/liter | 32 (22–50) | 36 (23–58) |
| Median creatinine clearance by Cockcroft–Gault (IQR) — ml/min | 106 (80–142) | 103 (80–140) |
*
Percentages may not total 100 because of rounding. ALT denotes alanine aminotransferase, AST aspartate aminotransferase, and IQR interquartile range.
†
Race was reported by the patients.
‡
The body-mass index is the weight in kilograms divided by the square of the height in meters.
§
P=0.02 for the comparison between the 5-day group and the 10-day group by the Wilcoxon rank-sum test.
¶
P=0.008 for the comparison between the 5-day group and the 10-day group by the Wilcoxon rank-sum test.